Sep 13, 2022 / 03:45PM GMT
Unidentified Analyst -
All right. So I got to read this first. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley reps -- sales reps. All right.
All right, Shawn, it was good to see you today. I just want to start off with those who are not familiar with VistaGen's story and social anxiety disorder. Can you give us an overview of VistaGen and your PALISADE Phase III Program for social anxiety disorder?
Shawn K. Singh - VistaGen Therapeutics, Inc. - CEO & Director
Great. Yes, absolutely, Scott. Thanks for the chance to speak with you today. I'll be making forward-looking statements of normal disclaimers associated with it.
VistaGen is a late-stage CNS-focused company with a Phase III program in development in social anxiety disorder. We have a second program, PH10, that's in Phase II development for major
VistaGen Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers